108833-49-4

Basic information

• Product Name: 2(1H)-Quinoxalinone,6-methoxy-3-methyl-(9CI)
• Synonyms: 2(1H)-Quinoxalinone,6-methoxy-3-methyl-(9CI);6-METHOXY-3-METHYLQUINOXALIN-2(1H)-ONE
• CAS NO: 108833-49-4
• Molecular Formula: C10 H10 N2 O2
• Molecular Weight: 0
• Product Categories: PIPERIDINE
• Mol File: 108833-49-4.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2(1H)-Quinoxalinone,6-methoxy-3-methyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2(1H)-Quinoxalinone,6-methoxy-3-methyl-(9CI)(108833-49-4)
• EPA Substance Registry System: 2(1H)-Quinoxalinone,6-methoxy-3-methyl-(9CI)(108833-49-4)

Safety Data

• Hazardous Substances Data: 108833-49-4(Hazardous Substances Data)

Usage

Structure

Quinoxalinone derivative with a methoxy group at position 6 and a methyl group at position 3

Biological significance

Has potential pharmacological activities

Pharmacological properties

Exhibits antioxidant, anti-inflammatory, and antimicrobial properties

Potential applications

Development of new drugs

Current status

Ongoing research on pharmacological effects and potential applications. Further studies are needed to fully understand its properties and uses.

Upstream product

• 127-17-3 2-oxo-propionic acid 
• 102-51-2 4-methoxy-1,2-phenylenediamine 
• 617-35-6 2-oxo-propionic acid ethyl ester 
• 868771-43-1 6-methoxy-3-methyl-3,4-dihydro-1H-quinoxalin-2-one 
• 505065-41-8 2-chloro-N-(4-methoxy-2-nitro-phenyl)-propionamide 
• 868771-33-9 N-(2-amino-4-methoxy-phenyl)-2-chloro-propionamide 
• 40781-31-5 2-chloro-N-(4-methoxy-phenyl)propionamide 
• 104-94-9 4-methoxy-aniline 
• 446-38-8 2-fluoro-4-methoxy-1-nitro-benzene 

Downstream Products

• 1392412-99-5 1-(2-chlorophenyl)-7-methoxy-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline 

Relevant articles and documents

Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants

A substrate envelope-guided design strategy is reported for improving the resistance profile of HCV NS3/4A protease inhibitors. Analogues of 5172-mcP1P3 were designed by incorporating diverse quinoxalines at the P2 position that predominantly interact with the invariant catalytic triad of the protease. Exploration of structure-activity relationships showed that inhibitors with small hydrophobic substituents at the 3-position of P2 quinoxaline maintain better potency against drug resistant variants, likely due to reduced interactions with residues in the S2 subsite. In contrast, inhibitors with larger groups at this position were highly susceptible to mutations at Arg155, Ala156, and Asp168. Excitingly, several inhibitors exhibited exceptional potency profiles with EC50 values ≤5 nM against major drug resistant HCV variants. These findings support that inhibitors designed to interact with evolutionarily constrained regions of the protease, while avoiding interactions with residues not essential for substrate recognition, are less likely to be susceptible to drug resistance.

TRIAZOLOPYRAZINE DERIVATIVES AND THEIR USE FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS

The present invention is directed to triazolopyrazine compounds of Formula (I). Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds as therapeutic agents treating neurological and psychiatric disorders.

Novel approach to 3-methyl-1H-quinoxalin-2-ones

A novel approach to the synthesis of 3-methyl-1H-quinoxalin-2-ones has been described. These compounds were regioselectively prepared by starting from substituted phenylamines and α-chloropropionyl chloride through the efficient procedures of acylation, nitration, reduction, intramolecular alkylation, and oxidation. Copyright Taylor & Francis, Inc.